RAPP – rapport therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? [Yahoo! Finance]
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Rapport Therapeutics (NASDAQ:RAPP) is now covered by analysts at BTIG Research. They set a "buy" rating and a $47.00 price target on the stock.
Form 4 Rapport Therapeutics, For: Nov 26 Filed by: Gault Cheryl
Form 4 Rapport Therapeutics, For: Nov 17 Filed by: Ceesay Abraham
Form 4 Rapport Therapeutics, For: Nov 17 Filed by: Bredt David
Form SCHEDULE 13G/A Rapport Therapeutics, Filed by: Cormorant Asset Management, LP
Form 10-Q Rapport Therapeutics, For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.